US2002094319A1PendingUtilityA1

The use of bacterial phage associated lysing enzymes for treating bacterial infections of the upper respiratory system

54
Priority: Oct 31, 1997Filed: Dec 11, 2001Published: Jul 18, 2002
Est. expiryOct 31, 2017(expired)· nominal 20-yr term from priority
Inventors:Vincent FischettiLawrence Loomis
C12N 9/503A61K 38/00Y02A50/30A61K 9/00
54
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

The present invention discloses a composition for treating bacterial infections of the mouth or teeth, comprising an effective amount of at least one lytic enzyme produced by bacteria infected with a bacteriophage specific for that bacteria and a pharmaceutically acceptable carrier for topical application of at least one lytic enzyme.

Claims

exact text as granted — not AI-modified
What we claim is:  
     
         1 ) A composition for treating bacterial infections of the mouth or teeth, comprising an effective amount of at least one lytic enzyme produced by bacteria infected with a bacteriophage specific for that bacteria and a pharmaceutically acceptable carrier for topical application of the at least one lytic enzyme.  
     
     
         2 ) The composition according to  claim 1 , wherein said composition is for treating of dental caries.  
     
     
         3 ) The composition according to  claim 2 , wherein said composition is used for prophylactic treatment of dental caries.  
     
     
         4 ) The composition according to  claim 2 , wherein said composition is used for therapeutic treatment of dental caries.  
     
     
         5 ) The composition according to  claim 1 , wherein said carrier is toothpaste.  
     
     
         6 ) The composition according to  claim 1 , wherein said carrier is an oral wash.  
     
     
         7 ) The composition according to  claim 1 , wherein said carrier is a chewing gum.  
     
     
         8 ) The composition according to  claim 1 , wherein said carrier is a lozenge.  
     
     
         9 ) The composition according to  claim 1 , wherein said bacteria being treated is Streptococcus mutans.  
     
     
         10 ) The composition according to  claim 1 , wherein said at least one lytic enzyme is present in an amount ranging from about 100 to about 500,000 units per milliliter.  
     
     
         11 ) The composition according to  claim 1 , wherein said at least one lytic enzyme is present in an amount ranging from about 10,000 to about 100,000 units per milliliter.

Join the waitlist — get patent alerts

Track US2002094319A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.